Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of BXOS110 in acute ischemic stroke
ChiCTR2600131353Phase 3Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jan 2025
- Modality
- Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in ischemic stroke comparing BXOS110 experimental group with Placebo group (2 arms). Primary endpoint: modified Rankin Scale score. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
recombinant human prourokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600131353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131353.